Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Lee BD, Dawson VL, Dawson TM.

Trends Pharmacol Sci. 2012 Jul;33(7):365-73. doi: 10.1016/j.tips.2012.04.001. Epub 2012 May 9. Review.

2.

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).

Deng X, Choi HG, Buhrlage SJ, Gray NS.

Expert Opin Ther Pat. 2012 Dec;22(12):1415-26. doi: 10.1517/13543776.2012.729041. Epub 2012 Nov 6. Review.

PMID:
23126385
3.

Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.

Estrada AA, Sweeney ZK.

J Med Chem. 2015 Sep 10;58(17):6733-46. doi: 10.1021/acs.jmedchem.5b00261. Epub 2015 May 14.

PMID:
25915084
4.

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.

Liu Z, Hamamichi S, Lee BD, Yang D, Ray A, Caldwell GA, Caldwell KA, Dawson TM, Smith WW, Dawson VL.

Hum Mol Genet. 2011 Oct 15;20(20):3933-42. doi: 10.1093/hmg/ddr312. Epub 2011 Jul 18.

5.

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.

Li T, Yang D, Zhong S, Thomas JM, Xue F, Liu J, Kong L, Voulalas P, Hassan HE, Park JS, MacKerell AD Jr, Smith WW.

Hum Mol Genet. 2014 Dec 1;23(23):6212-22. doi: 10.1093/hmg/ddu341. Epub 2014 Jul 3.

PMID:
24993787
6.

Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

Kramer T, Lo Monte F, Göring S, Okala Amombo GM, Schmidt B.

ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. doi: 10.1021/cn200117j. Epub 2012 Jan 18. Review.

7.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.

8.

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB.

J Biol Chem. 2015 Aug 7;290(32):19433-44. doi: 10.1074/jbc.M115.660001. Epub 2015 Jun 15.

9.

MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.

Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H.

Hum Mol Genet. 2013 Feb 1;22(3):608-20. doi: 10.1093/hmg/dds470. Epub 2012 Nov 2.

10.

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).

Kethiri RR, Bakthavatchalam R.

Expert Opin Ther Pat. 2014 Jul;24(7):745-57. doi: 10.1517/13543776.2014.907275. Epub 2014 Jun 11. Review.

PMID:
24918198
11.

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG.

Neurobiol Dis. 2010 Oct;40(1):73-81. doi: 10.1016/j.nbd.2010.04.002. Epub 2010 Apr 9.

12.

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.

Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, Morrow JA.

J Pharmacol Exp Ther. 2015 Dec;355(3):397-409. doi: 10.1124/jpet.115.227587. Epub 2015 Sep 25.

14.

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG.

Hum Mol Genet. 2013 Jan 15;22(2):328-44. doi: 10.1093/hmg/dds431. Epub 2012 Oct 12.

15.

Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.

Yun H, Heo HY, Kim HH, DooKim N, Seol W.

Bioorg Med Chem Lett. 2011 May 15;21(10):2953-7. doi: 10.1016/j.bmcl.2011.03.061. Epub 2011 Mar 21.

PMID:
21474311
16.

Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.

Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B.

Neurosci Lett. 2013 Aug 9;549:57-62. doi: 10.1016/j.neulet.2013.05.034. Epub 2013 May 28.

17.

Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Ray S, Liu M.

Future Med Chem. 2012 Sep;4(13):1701-13. doi: 10.4155/fmc.12.110. Review.

18.

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Sloan M, Alegre-Abarrategui J, Potgieter D, Kaufmann AK, Exley R, Deltheil T, Threlfell S, Connor-Robson N, Brimblecombe K, Wallings R, Cioroch M, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Dodson PD, Wade-Martins R.

Hum Mol Genet. 2016 Mar 1;25(5):951-63. doi: 10.1093/hmg/ddv628. Epub 2016 Jan 6.

19.

Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.

Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG.

Int J Biol Sci. 2011;7(6):753-61. Epub 2011 Jun 9.

20.

Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.

Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z.

J Neurochem. 2007 Oct;103(1):238-47. Epub 2007 Jul 10.

Supplemental Content

Support Center